TCTR20240604001尚未招募1 期
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Racecadotril 100 mg Capsules and Reference Product (HIDRASEC) in Healthy Thai Volunteers under Fasting Conditions
International Bio Service0 个研究点目标入组 44 人开始时间: 2024年6月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy Thai male or female subjects between the ages of 18 to 55 years. 2.Body mass index between 18.0 to 30.0 kg/m2. 3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4.Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 5.Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1: - Postmenopausal for at least 1 year or - Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months 6.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2. 7.Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
排除标准
- •1.History of allergic reaction or hypersensitivity to the active substance or to any of the excipients. 2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper/hypothyroidism, diabetes mellitus), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper/hypotension), psychiatric (e.g. depression), neurologic (e.g. convulsion), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness. 3.Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19. 4.History about administration of COVID-19 vaccine within 30 days prior to check-in in each Period. 5.History or evidence of angioedema. 6.History of febrile illness within 7 days prior to check-in in each period. 7.History or evidence of antibiotic-associated colitis such as pseudomembranous colitis. 8.History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 9.History of problems with swallowing tablet or capsule. 10.History of sensitivity to heparin or heparin-induced thrombocytopenia. 11.Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy. 12.History of diarrhea, dehydration or vomiting within 24 hours prior to check-in in each period. 13.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine). 14.Investigation with blood sample shows positive test for HBsAg. 15.Abnormal liver function, 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test. 16.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study. 17.History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy, etc.). 18.History or evidence of alcohol consumption or alcohol-containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study or alcohol breath test shows positive result. In case of alcohol breath test result represents the alcohol concentration range of 1 - 10 mg%BAC and the physician carefully considers that the value came from other reasons, not from the alcohol drinking behavior of subjects, the test will be repeated two times separately, not more than 10 minutes. The result of the last time should be used for subject eligibility which must be 0 mg%BAC. 19.History or evidence of habitual consume of tea, coffee, xanthine or caffeine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study. 20.Consume or drink juice of grapefruit or orange or pomelo or its supplement/containing products and cannot abstain for at least 7 days prior to check-in in Period 1 and continued for entire duration of the study. 21.Use of prescription
研究者
相似试验
尚未招募
4 期
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Lercanidipine 20 mg Film-coated Tablets and Reference Product (ZANIDIP) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20230120003International Bio Service48
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Dabigatran Etexilate Capsules 150 mg and Reference Product (Pradaxa) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersDabigatran etexilate 150 mg Capsules in Healthy Thai VolunteersTCTR20230427002International Bio Service Co.,Ltd48
已完成
不适用
A Bioequivalence Study of Capecitabine 500 mg with Xeloda® 500 mg in Adult Cancer Patients Under Fed Condition.CTRI/2021/09/036815SP Accure Labs Pvt Ltd33
尚未招募
1 期
A Single-dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Full Replicate Crossover Bioequivalence Study of Generic Edoxaban 60 mg Film-coated Tablets (Unison Laboratories Co., Ltd.) and Reference Product (Lixiana) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study of Edoxaban 60 mg Film-coated Tablets in Healthy Thai Volunteers under Fasting ConditionsTCTR20230826003nison Laboratories Co., Ltd.30
已完成
Unknown
An single dose, two-treatment, two-way crossover study of study product containing glutathione, in healthy, adult, human subjects under fasting conditions.CTRI/2023/08/056674YourZooki holdings Ltd24